Overview

Methylene Blue in Early Septic Shock

Status:
Completed
Trial end date:
2021-01-25
Target enrollment:
Participant gender:
Summary
Septic shock is a subset of sepsis characterized by a decrease in vascular tone, which contributes to impaired regional blood flow distribution, and leads to organic failure. Besides intravenous fluids and adequate antimicrobial therapy, patients with septic shock require vasopressor support, which can lead to many adverse effects, therefore, non-vasopressor agents that can improve hemodynamic status are needed. In this randomized controlled-study, the investigators will address the efficacy and safety of infusion with methylene blue in patients with septic shock.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hospital Civil de Guadalajara
Treatments:
Methylene Blue